Aquestive Therapeutics, Inc. Proceeds from Long-Term Debt Issued
Aquestive Therapeutics, Inc. (AQST) reported Proceeds from Long-Term Debt Issued of $54.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-08-11
- 2026-06-30: Proceeds from Issuance of Long-term Debt 6 month $54.34M.
- 2025-06-30: Proceeds from Issuance of Long-term Debt 6 month $0.00.
- 2023-06-30: Proceeds from Issuance of Long-term Debt 6 month $0.00.
- 2022-06-30: Proceeds from Issuance of Long-term Debt 6 month $3.81M.
| Period end | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month |
|---|---|---|
| 2026-06-30 | $54.34M 10-Q · filed 2026-08-11 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-11 | |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-07 | |
| 2022-06-30 | $3.81M 10-Q · filed 2023-08-07 | |
| 2019-09-30 | $70.00M 10-Q · filed 2019-11-05 | |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |